Semaglutide for NASH: Can a GLP-1 Drug Reverse Fatty Liver Disease?

Medically reviewed by Dr. James Whitfield, DO, FACOI

Non-alcoholic steatohepatitis (NASH) affects millions worldwide with no approved pharmacotherapy. A Phase 2 trial published in the NEJM showed semaglutide resolved NASH in 59% of patients — nearly four times the placebo rate. This article examines the complete liver disease clinical trial data for semaglutide.

Semaglutide and Liver Disease: A New Therapeutic Frontier

Non-alcoholic steatohepatitis (NASH), now increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH), is one of the most prevalent chronic liver diseases worldwide, affecting an estimated 3-5% of the global population. Despite its prevalence, there are very few approved pharmacotherapies specifically for NASH. The discovery that semaglutide can resolve NASH in a significant proportion of patients represents one of the most promising developments in hepatology [1].

The Phase 2 NASH Trial (NEJM 2021)

The landmark Phase 2 trial, published in the New England Journal of Medicine in March 2021 by Newsome et al., was the first randomized controlled trial to evaluate semaglutide specifically for NASH treatment [1].

Study Design:

320 patients with biopsy-confirmed NASH (fibrosis stages F1-F3)

Randomized to once-daily subcutaneous semaglutide (0.1 mg, 0.2 mg, or 0.4 mg) or placebo

Treatment duration: 72 weeks

Primary endpoint: Resolution of NASH without worsening of fibrosis

Key secondary endpoint: Improvement in fibrosis without worsening of NASH

NASH Resolution Results:

Semaglutide 0.1 mg: 40% achieved NASH resolution

Semaglutide 0.2 mg: 36%

Semaglutide 0.4 mg: 59% achieved NASH resolution

Placebo: 17%

Odds ratio for 0.4 mg vs. placebo: 6.87 (95% CI, 2.60-17.63; P<0.001)

Fibrosis Results:

Improvement in fibrosis stage (≥1 stage): 43% with semaglutide 0.4 mg vs. 33% with placebo

This difference was not statistically significant (P=0.48)

Worsening of fibrosis: 5% with semaglutide 0.4 mg vs. 19% with placebo

The disconnect between impressive NASH resolution and modest fibrosis improvement became a key discussion point in the hepatology community [1].

---

> Interested in starting a supervised protocol? Telegenix offers telehealth peptide and TRT programs with ongoing lab monitoring and provider support. Book your free consultation today.

---

Understanding the Histological Findings

The liver biopsy data revealed nuanced effects of semaglutide on liver histology:

NAS (NAFLD Activity Score) Improvements:

Mean NAS improvement was significantly greater with semaglutide across all doses

Improvements were seen in all three NAS components: steatosis, lobular inflammation, and hepatocyte ballooning

The most dramatic improvement was in steatosis (fat content), consistent with semaglutide's metabolic effects

Liver Enzyme Improvements:

ALT (alanine aminotransferase): Significant reductions with semaglutide

AST (aspartate aminotransferase): Significant reductions

GGT (gamma-glutamyl transferase): Significant reductions

These biochemical improvements correlated with histological improvement [1].

The Cirrhosis Trial (Lancet 2023)

A separate Phase 2 trial evaluated semaglutide in patients with NASH and compensated cirrhosis (fibrosis stage F4), published in The Lancet Gastroenterology & Hepatology in 2023 by Loomba et al. [2].

Key Findings:

71 patients with NASH-related compensated cirrhosis

Semaglutide 2.4 mg once weekly vs. placebo for 48 weeks

NASH resolution without worsening fibrosis: 26.2% semaglutide vs. 9.7% placebo

Fibrosis improvement (≥1 stage): Not significantly different from placebo

No worsening of hepatic or renal function

The cirrhosis trial results were more modest than the non-cirrhotic trial, suggesting that semaglutide may be more effective in earlier stages of liver disease before irreversible fibrotic changes occur [2].

Mechanisms of Hepatoprotection

Semaglutide's beneficial effects on the liver appear to involve multiple mechanisms:

Weight loss and metabolic improvement: Reducing adiposity decreases hepatic fat delivery and improves insulin resistance, the primary driver of NASH.

Direct hepatic effects: GLP-1 receptors are expressed on hepatocytes, and GLP-1 receptor activation may directly reduce hepatic lipogenesis and inflammation.

Anti-inflammatory effects: Semaglutide reduces systemic inflammation (as measured by CRP), which may contribute to reduced hepatic inflammation.

Improved lipid metabolism: Enhanced fatty acid oxidation and reduced de novo lipogenesis in the liver.

Non-Invasive Biomarker Data

The NASH trials also evaluated non-invasive biomarkers that could be used to monitor treatment response without repeated liver biopsies:

FibroScan (liver stiffness): Improved with semaglutide treatment

MRI-PDFF (liver fat fraction): Dramatically reduced, correlating with histological steatosis improvement

FIB-4 index: Improved, suggesting reduced fibrosis burden

Enhanced Liver Fibrosis (ELF) score: Modest improvements

These biomarker findings support the development of non-invasive monitoring strategies for semaglutide-treated NASH patients [1].

Ongoing Phase 3 Development

Based on the Phase 2 results, Novo Nordisk launched the ESSENCE Phase 3 program evaluating semaglutide 2.4 mg for NASH:

ESSENCE trial: Large-scale Phase 3 trial in non-cirrhotic NASH patients

Primary endpoints include NASH resolution and fibrosis improvement

Results are expected to support potential regulatory approval for NASH indication

If successful, semaglutide could become one of the first approved pharmacotherapies specifically for NASH

Clinical Perspective

The semaglutide NASH data highlights both promise and limitations:

Strengths:

Impressive NASH resolution rates (59% at highest dose)

Well-characterized safety profile from extensive obesity/diabetes experience

Addresses the metabolic root cause of NASH

Dual benefit for patients with obesity and NASH

Limitations:

Fibrosis improvement was not statistically significant

Less effective in advanced (cirrhotic) disease

Requires ongoing treatment (chronic disease model)

Cost and access remain barriers for many patients

> Related Comparison: Ozempic vs Mounjaro: Complete Comparison

References

Newsome PN, Buchholtz K, Cusi K, et al. "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis." New England Journal of Medicine. 2021;384(12):1113-1124. PubMed: 33185364

Loomba R, Abdelmalek MF, Armstrong MJ, et al. "Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial." The Lancet Gastroenterology & Hepatology. 2023;8(6):511-522. PubMed: 36934740

---

> From research to results — get expert guidance. Telegenix specializes in physician-supervised peptide therapy and testosterone optimization. Schedule your free consultation and start your personalized protocol.

---